Encapsulated papillary carcinoma of the breast: a study of invasion associated markers
- Department of Histopathology, University of Nottingham, Nottingham University Hospitals NHS Trust, Nottingham, UK
- Correspondence to Dr Emad A Rakha, Department of Histopathology, Nottingham University Hospital NHS Trust, City Hospital Campus, Hucknall Road, Nottingham NG5 1PB, UK;
Contributors MT: staining and scoring. AG: staining and scoring and technical and scientific support. EJ: scoring. IOE: supervision, support and manuscript review. EAR: hypothesis, manuscript writing and data analysis.
- Accepted 4 April 2012
- Published Online First 3 May 2012
Encapsulated papillary carcinoma (EPC) of the breast is a distinct histological subtype characterised by malignant epithelial proliferation supported by fibrovascular stalks. Although EPC typically lacks myoepithelial cells, it shows indolent clinical course. The classification of EPC as an in situ, or invasive disease, remains a matter of debate.
Methods In this study, the authors investigated a panel of invasion-associated markers in a series of EPC and compared their expression with control groups of non-papillary ductal carcinoma in situ (DCIS) and conventional invasive carcinomas. The expression pattern of four matrix metalloproteinases (MMP-1, MMP-2, MMP-7 and MMP-9), transforming growth factor receptor beta, vascular endothelial growth factor (VEGF) and E-cadherin were assessed in the tumour cell and/or stromal tissue, and the results were analysed.
Results EPC showed higher expression levels of both MMP-1 and MMP-9 compared with DCIS, and no significant differences were observed between EPC and invasive carcinoma. Expression of MMP-2 and MMP-7 levels were similar in EPC and DCIS, but both showed lower levels compared with invasive tumours. EPC showed higher expression of E-cadherin and transforming growth factor receptor ß1 compared with both DCIS and invasive cancer. No difference in the stromal expression of MMPs or tumour expression of VEGF was detected.
Conclusion EPC exhibits an expression pattern of invasion-associated markers, which is intermediate in nature between DCIS and invasive cancer, providing further support of the unique biological features of EPC, and which may explain its clinically indolent behaviour.
- Human breast carcinoma
- encapsulated papillary carcinoma
- invasion-associated markers
- molecular pathology
- molecular biology
- breast cancer
- steroid receptors
EAR and MT contributed equally to the project.
Competing interests None.
Patient consent Obtained.
Ethics approval The ethics approval was provided by the Nottingham Researchl Ethics Committee 2.
Provenance and peer review Not commissioned; externally peer reviewed.